DEVELOPMENT AND IN-VITRO EVALUATION OF LIQUISOLID COMPACTS OF LORNOXICAM

The present study is undertaken with an aim to improve the dissolution profile and availability of a poorly soluble drug, Lornoxicam, through the development of liquisolid tablets. Liquisolid compacts were prepared by employing PEG 400, Avicel PH 112, and Aerosil 200 as solvent, carrier and coating materials, respectively. The flow properties of the drug improved significantly after formulating it into the liquisolid compacts. The post-compressional parameters of prepared tablets revealed the uniformity and maintenance of standards within the different batches. In-vitro drug release studies showed significant improvement in the dissolution of lornoxicam in its liquisolid form compared to a commercial product. The effect of formulation parameters, such as drug concentration and carrier to coat ratio, on enhancing drug dissolution, was also explored. FT-IR, DSC and XRD techniques were employed for the physical characterization of the drug in the liquisolid systems. The drug release from the optimized liquisolid compacts (F8) followed first-order release kinetics.